The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

dc.contributor.authorAkyildiz, Arif
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorOzluk, Ahmet Anil
dc.contributor.authorIsmayilov, Rashad
dc.contributor.authorMutlu, Emel
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorYildiz, Ibrahim
dc.contributor.authorIriagac, Yakup
dc.contributor.authorTurhal, Serdar
dc.contributor.authorAkbas, Sinem
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorTelli, Tugba Akin
dc.contributor.authorTurkoz, Fatma Paksoy
dc.contributor.authorOzcelik, Melike
dc.contributor.authorErciyestepe, Mert
dc.contributor.authorSelvi, Oguzhan
dc.contributor.authorGulbagci, Burcu
dc.contributor.authorErturk, Ismail
dc.contributor.authorIsleyen, Zehra Sucuoglu
dc.contributor.authorKahraman, Seda
dc.contributor.authorAkdag, Mutianur Ozkorkmaz
dc.contributor.authorHamitoglu, Buket
dc.contributor.authorUnek, Ilkay Tugba
dc.contributor.authorUnal, Caglar
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorArslan, Cagatay
dc.contributor.authorAzizy, Abdulmunir
dc.contributor.authorHelvaci, Kaan
dc.contributor.authorDemirci, Umut
dc.contributor.authorDizdar, Omer
dc.contributor.authorBasaran, Mert
dc.contributor.authorGoker, Erdem
dc.contributor.authorSendur, Mehmet Ali
dc.contributor.authorYalcin, Suayib
dc.date.accessioned2025-10-16T15:14:15Z
dc.date.issued2023
dc.identifier.doi10.1097/MD.0000000000035950
dc.identifier.otherWOS:001103423000055
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6108
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceMEDICINE
dc.subjectatezolizumab
dc.subjectbevacizumab
dc.subjecthepatocellular carcinoma
dc.subjectimmunotherapy
dc.titleThe safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
dc.typeArticle

Dosyalar

Koleksiyonlar